Phase 3 data from BioNTech and partner OncoC4 showed a CTLA‑4–targeting antibody improved overall survival in a lung cancer study but raised tolerability concerns that could complicate use. The trial demonstrated a statistically significant survival advantage versus control, yet analysts flagged a challenging adverse‑event profile that may limit broad adoption without mitigation strategies. The companies plan deeper safety analyses and regulator discussions as they weigh next steps for filings and label strategy.